Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

1.0K
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
1.0K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

360
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
360
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

428
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
428
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

1.4K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.4K
Nonlinear Pharmacokinetics: Causes of Nonlinearity01:22

Nonlinear Pharmacokinetics: Causes of Nonlinearity

936
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
936
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

806
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
806

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons.

The Journal of infectious diseases·2026
Same author

Correction: How convincing is a matching Y-chromosome profile?

PLoS genetics·2026
Same author

Levofloxacin in Bone and Joint Infections: Development of an Application for Model-Informed Precision Dosing.

Clinical pharmacology and therapeutics·2025
Same author

Model-based approach for two-stage group sequential or adaptive designs in bioequivalence studies using parallel and crossover designs.

Statistical methods in medical research·2025
Same author

Recent Statistical Innovations in Human Genetics.

Annals of human genetics·2025

Related Experiment Video

Updated: May 6, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K

Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic

Julie Bertrand1, David J Balding

  • 1Genetics Institute, University College London Genetics Institute, London, UK. j.bertrand@ucl.ac.uk

Pharmacogenetics and Genomics
|January 23, 2013
PubMed
Summary

Penalized regression methods efficiently analyze how multiple single nucleotide polymorphisms (SNPs) affect drug pharmacokinetics (PK). These methods offer a computationally faster alternative to stepwise procedures for genetic covariate analysis in PK studies.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

2.9K

Related Experiment Videos

Last Updated: May 6, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

2.9K

Area of Science:

  • Pharmacogenomics
  • Computational Biology
  • Statistical Genetics

Background:

  • Traditional pharmacokinetic (PK) studies often analyze drug concentration or area under the curve.
  • Nonlinear mixed effects models can analyze entire PK curves, even with sparse data.
  • Systematic methods for assessing multiple single nucleotide polymorphisms (SNPs) in PK models were previously lacking.

Purpose of the Study:

  • To evaluate various penalized regression techniques for incorporating SNPs into PK analyses.
  • To compare the performance of penalized regression methods against traditional approaches.

Main Methods:

  • Simulated 200 datasets with 300 participants each, generating 1227 genotypes via haplotypes.
  • Modeled PK profiles using expectation maximization and investigated genetic associations with parameters.
  • Compared stepwise regression, modified ridge regression, Lasso, and HyperLasso.

Main Results:

  • Penalized regression methods, particularly HyperLasso and Lasso, demonstrated comparable statistical power to stepwise procedures.
  • Ridge regression showed fewer true positives compared to stepwise and HyperLasso.
  • Penalized regression approaches were significantly faster computationally than the stepwise method.

Conclusions:

  • Penalized regression methods are computationally efficient for PK analyses involving numerous genetic covariates.
  • All evaluated methods, except ridge regression, exhibited similar statistical power.
  • Penalized regression is recommended over stepwise procedures for analyzing large panels of genetic covariates in PK studies.